Allosteric Targeting Of The Dopamine D2 Receptor: A Novel Approach For The Treatment Of Parkinson’s Disease And Schizophrenia [ 2016 - 2018 ]

Research Grant

Researchers: Dr Jonathan Lane (Principal investigator) ,  Dr Ben Capuano ,  Prof Maarten Van Den Buuse

Brief description The dopamine D2 receptor is a brain protein that is the target for drugs that are used in the treatment of schizophrenia and Parkinson's disease (PD). In both cases the current drugs have significant side effects because they simply act to switch the receptor off or on respectively. We will focus on a new class of drugs that, because they act to tune up or tune down the activity of the D2 receptor, may be a safer more effective approach to treat these disorders.

Funding Amount $AUD 484,258.87

Funding Scheme Project Grants

Notes Standard Project Grant